Veracyte, Inc.
VCYT
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $3.4B
$42.53
▼ -4.79%
P/E
29.95
Mkt Cap
$3.4B
52-Wk Range
$29.46–$60.91
52-Week Range
$29.46 - $60.91
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 31.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary genomic sequencing and machine learning algorithms with clinical validation
- Broad multi-cancer portfolio reducing customer switching and increasing wallet share
- Strategic partnerships with Johnson & Johnson and other major healthcare companies
- Strong intellectual property portfolio protecting core diagnostic technologies
Bear Case
1 risk
- Above-average volatility (beta 1.9).
Growth
Stable outlook
Increasing adoption of precision medicine and genomic testing in oncology
Value
Fairly valued vs Biotech & Therapeutics peers
Momentum
Weak
-10.0% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying VCYT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
JUL 30, 2026
Reported EPS of $0.54 vs $0.41 consensus (+31.6% surprise). Revenue of $150.3M vs $144.6M expected (+4.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+31.6%
Revenue trend · last 8Q
—
+21%
+18%
+14%
+14%
+19%
+21%
+15%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$115.9M
$118.6M
$114.5M
$130.2M
$131.9M
$140.6M
$139.1M
$150.3M
Margins · last 8Q
Gross
72.6%
Operating
14.5%
Profit
17.0%
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
$65.00
▲ +52.8% vs $42.53
Latest: Needham · Jul 31, 2026
1 analyst covering
vs Industry
How VCYT stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related